Research
Molecular
The review discusses emerging therapeutic strategies for MASLD and its associated comorbidities.
Practitioners should stay informed about new treatment options for MASLD and its comorbidities.
StrongSupportsmedium confidence
In addition, we discuss emerging therapeutic strategies for MASLD/NAFLD and its associated comorbidities.
Why this rating
The claim is based on a review of current evidence.
Source
Extrahepatic manifestation of metabolic dysfunction-associated steatotic liver disease
Anoushka Shenoy et al. · Metabolism and Target Organ Damage · 2025
DOI 10.20517/mtod.2025.73
reviewCited 2×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Molecular
- QRISK decreased markedly after weight loss from 18.9 ± 2.2% to 11.2 ± 1.6%, p < 0.0001.Strong
- Normalization of 10-year cardiovascular risk and heart age is possible after substantial dietary weight loss and remission of T2DM.Strong
- The Low-Fat Plus diet resulted in a greater reduction in total cholesterol compared to the Low-Fat diet, with changes of -0.46 mmol/L (-17.6 mg/dL) versus -0.24 mmol/L (-9.2 mg/dL) respectively (P = 0.01).Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →